Navigation Links
Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
Date:7/30/2008

SAN CARLOS, Calif., July 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2008 on Wednesday, August 6, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, August 20, 2008.

To access the conference call, follow these instructions:

Dial: (866) 831-5605 (U.S.); (617) 213-8851 (international)

Passcode: 33430853 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, August 20, 2008 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 67859021.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar's technology and drug development exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstCall/ ... leading provider of tools and services for drug d...ced Living Image 4.0 software for IVIS® in vi...he more than 800 Caliper IVIS systems currently in...0 features advanced spectral unmixing tools to enh...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Reportlink... is available in its catalogue: ,, Carbondioxi... http://www.reportlinker.com/p0164368/Carbondioxi... ,, Incubators are the most critical equipment ...and other applications for providing a controlled ...
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/ - On...y") (TSX:ONC; NASDAQ: ONCY ) announced today that ...ffering, the underwriters have exercised in full t...onal 637,500 units. Each unit is comprised of one ...rrant, and was sold at a price of US$3.00 per unit...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte ...l oral JAK2 inhibitor, SB1518, at The American Soc...ion in New Orleans. ,, Data will be presented o...ation trial of SB1518 detailing its safety, tolera... profile in dose levels ranging from 100 to 600 mg...
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...al School Researchers Used Thermo Scientific Dharm... for Reproduction of the Virus that ...31 Thermo Fisher,Scientific Inc., the world leade...-interference (RNAi) technology has enabled a grou...on, which identified human proteins,required for g...
... Manufacture ARIUS, Product Candidate Trop-2 Signa... PRINCETON, N.J., Jan. 31 Laureate Pharma, Inc., ...protein production company, today,announced that i...greement,with ARIUS Research, Inc., a biotechnolog...e next wave of antibody therapeutics to treat canc...
...d Balance Sheet and Advancing Products in 2008 - .... Eastern Time -, BRANFORD, Conn., Jan. 31 CuraG... consolidated financial results for the,fourth qua...raGen reported a loss from operations for the four...share, which included restructuring charges,totali...
Other Biology Technology:Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 2Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 3Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 4Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 5Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 2CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 5CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 6CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 7
(Date:12/3/2009)...n Antarctic snowmelt that occurred during the 2008...rong positive phases for two main climate drivers,...thern Hemisphere Annular Mode), according to Dr. M...pheric Sciences at The City College of New York. ...l faculty at the CUNY Graduate Center, added that ...
(Date:12/2/2009)... who smoke their first cigarette within minutes af... a by-product of nicotine when processed by the bo...e number of cigarettes smoked. , "Since cotin...er, our results suggest that smokers who smoke imm...r lung cancer," said researcher Joshua E. Muscat, ...
(Date:12/2/2009)..., peanut butter, and other foods have done more th...afety. They also are quietly fueling a boom in the...ew food safety regulations. That,s the topic of th...emical & Engineering News , (C&EN) ACS, weekly new...ey and Senior Correspondent Marc Reisch point out ...
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2Is Smoking Tougher on Women 3F 60033 1Is Smoking Tougher on Women 3F 60033 2Is Smoking Tougher on Women 3F 60033 3New Study Confirms VASER Lipo Results Are Superior to Standard Liposuction 5670 1New Study Confirms VASER Lipo Results Are Superior to Standard Liposuction 5670 2Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 1Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 2
...searchers at Harvard Medical School and Massachuse...at the 13th European Cancer Conference (ECCO) have...ery is possible using nanoparticle-apatamer conjug...mers) are short DNA or RNA fragments that can bind...nity; analogous to monoclonal antibodies. In the f...
... to suppress HIV replication and has dramatically ...d patients. But the existence of viral reservoirs...eated patients. In a new study appearing on Novemb...-Wook Chun and colleagues from the NIH offer new i...ividuals receiving antiviral therapy. , The autho...
...ocally the coolest - pieces of real estate on the ...g a state-of-the-art superconducting magnet for us... DNA, RNA, enzymes and other proteins. , The inst...r magnet was recently completed in a specially bui...n and a half tons, the magnetic resonance (MR) spe...
Other Biology News:Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 2Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 3Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 4Superconducting magnet attracts molecular research 2
Mouse Anti-Human Flavocytochrome b Monoclonal Antibody, FITC Conjugated, Clone 7D5 from MBL International
Chaps Cell Extract Buffer (10X) from Cell Signaling Technology
Rabbit Anti-Human Reptin / TIP49B / RUVB2 Polyclonal Antibody, Unconjugated from Abcam
Anti-Human L-Ficolin Monoclonal Antibody, Unconjugated, Clone GN4 from Cell Sciences
Biology Products: